The cardioprotective effect of dual metallopeptidase inhibition: Respective roles of endogenous kinins and natriuretic peptides

Canadian Journal of Physiology and Pharmacology

Volumn 83, Issue 2, 2005, Pages 166-173

  Dumoulin, Marie Josée ^a   Adam, Albert ^a   Burnett, John ^b   Heublein, Denise ^b   Yamaguchi, Nobuharu ^a   Lamontagne, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

ACE inhibitors; Bradykinin; Ischemia; Natriuretic peptide; Omapatrilat; Reperfusion

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ[1-8]; BRADYKININ[8 LEUCINE 9 DEARGININE]; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANYLATE CYCLASE A RECEPTOR BLOCKING AGENT; GUANYLATE CYCLASE B RECEPTOR BLOCKING AGENT; HS 142 1; ICATIBANT; KININ; LACTATE DEHYDROGENASE; LYSYLBRADYKININ[8 LEUCINE 9 DEARGININE]; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; NATRIURETIC FACTOR; NORADRENALIN; OMAPATRILAT; RAMIPRIL; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INHIBITION; ENZYME RELEASE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; ISOLATED HEART; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; HEMODYNAMIC PROCESSES; KININS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; NEPRILYSIN; PYRIDINES; RAMIPRIL; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RECEPTORS, ATRIAL NATRIURETIC FACTOR; THIAZEPINES;

EID: 18844424283     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y04-134     Document Type: Article

References (34)

1. Blais, C.J., Marc-Aurele, J., Simmons, W.H., Loute, G., Thibault, P., Skidgel, R.A., and Adam, A. 1999a. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides, 20: 421-430.
2. Blais, C.J., Rouleau, J.L., Brown, N.J., Lepage, Y., Spence, D., Munoz, C. et al. 1999b. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology, 43: 293-302.
3. Blais, C.J., Fortin, D., Rouleau, J.L., Molinaro, G., and Adam, A. 2000a. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J. Pharmacol. Exp. Ther. 295: 621-626.
4. Blais, C.J., Marceau, F., Rouleau, J.L., and Adam, A. 2000b. The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides, 21: 1903-1940.
5. Carlsson, L., and Abrahamsson, T. 1989. Ramiprilat attenuates the local release of noradrenaline in the ischemic myocardium. Eur. J. Pharmacol. 166: 157-164.
6. Cyr, M., Hume, H.A., Champagne, M., Sweeney, J.D., Blais, C.J., Gervais, N., and Adam, A. 1999. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study. Transfusion, 39: 1084-1088.
7. Décarie, A., Drapeau, G., Closset, J., Couture, R., and Adam, A. 1994. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides, 15: 511-518.
8. Dogan, R., Farsak, B., Isbir, S., Sarigul, A., Tuncer, M., and Kilinc, K. 2001. Protective effect of lisinopril against ischemia-reperfusion injury in isolated guinea pig hearts. J. Cardiovasc. Surg. (Torino), 42: 43-48.
9. Dumoulin, M.-J., Adam, A., Blais, C.J., and Lamontagne, D. 1998. Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc. Res. 38: 229-236.
10. Dumoulin, M.-J., Adam, A., Rouleau, J.L., and Lamontagne, D. 2001. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J. Cardiovasc. Pharmacol. 37: 359-366.
11. Dumoulin, M.-J., Adam, A., Rouleau, J.L., Gosselin, H., and Lamontagne, D. 2003. Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction. Can. J. Physiol. Pharmacol. 81: 740-746.
12. Fleetwood, G., Boutinet, S., Meier, M., and Wood, J.M. 1991. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J. Cardiovasc. Pharmacol. 17: 351-356.
13. Frimm, C., Sun, Y., and Weber, K.T. 1996. Wound healing following myocardial infarction in the rat: role for bradykinin and prostaglandins. J. Mol. Cell. Cardiol. 28: 1279-1285.
14. Lagneux, C., Adam, A., and Lamontagne, D. 2003. A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int. Immunopharmacol. 3: 1511-1518.
15. Lamontagne, D., Yamaguchi, N., Nadeau, R., de Champlain, J., Godin, D., and Campeau, N. 1986. Effects of sotalol, (-)-propranolol and prazosin on reperfusion-induced arrhythmias and increased cardiac norepinephrine release. Eur. J. Pharmacol. 123: 1-10.
16. 9-bradykinin release following reperfusion of the ischaemic rat heart. Br. J. Pharmacol. 115: 476-478.
17. Linz, W., and Schölkens, B.A. 1987. Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J. Cardiovasc. Pharmacol. 10(Suppl. 7): S75-S82.
18. Linz, W., and Schölkens, B.A. 1992. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br. J. Pharmacol. 105: 771-772.
19. Linz, W., Schölkens, B.A., and Han, Y.F. 1986. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J. Cardiovasc. Pharmacol. 8(Suppl. 10): S91-S99.
20. Massoudy, P., Becker, B.F., and Gerlach, E. 1994. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat. J. Cardiovasc. Pharmacol. 23: 632-639.
21. Nolly, H., and Nolly, A. 1998. Release of endothelial-derived kallikrein, kininogen and kinins. Biol. Res. 31: 169-174.
22. Orawski, A.T., and Simmons, W.H. 1995. Purification and properties of membrane-bound aminopeptidase P from rat lung. Biochemistry, 34: 11227-11236.
23. Raut, R., Rouleau, J.L., Blais, C.J., Gosselin, H., Molinaro, G., Sirois, M.G. et al. 1999. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am. J. Physiol. 276: H1769-H1779.
24. 9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J. Immunol. Methods, 180: 247-257.
25. Remie, R., and Zaagsma, J. 1986. A new technique for the study of vascular presynaptic receptors in freely moving rats. Am. J. Physiol. 251: H463-H467.
26. Schölkens, B.A., Linz, W., and Konig, W. 1988. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist. J. Hypertens. Suppl. 6: S25-S28.
27. Schömig, A., Dart, A.M., Dietz, R., Kubler, W., and Mayer, E. 1985. Paradoxical role of neuronal uptake for the locally mediated release of endogenous noradrenaline in the ischemic myocardium. J. Cardiovasc. Pharmacol. 7(Suppl. 5): S40-S44
28. Steiner, A.L., Parker, C.W., and Kipnis, D.M. 1972. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J. Biol. Chem. 247: 1106-1113.
29. Trippodo, N.C., Robl, J.A., Asaad, M.M., Fox, M., Panchal, B.C., and Schaeffer, T.R. 1998. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am. J. Hypertens. 11: 363-372.
30. Unger, T., Mattfeldt, T., Lamberty, V., Bock, P., Mall, G., Linz, W. et al. 1992. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension, 20: 478-482.
31. Wiemer, G., Popp, R., Schölkens, B.A., and Gogelein, H. 1994. Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cells. Brain Res. 638: 261-266.
32. Yamaguchi, N. 1993. In vivo evidence for adrenal catecholamine release mediated by nonnicotinic mechanism: local medullary effect of VIP. Am. J. Physiol. 265: R766-R771.
33. Yamaguchi, N., Kimura, T., Lamontagne, D., de Champlain, J., and Nadeau, R. 1990. Occlusion time dependency of regional noradrenaline release and cardiac arrhythmias during reperfusion of acutely ischaemic heart in the dog in vivo. Cardiovasc. Res. 24: 688-696.
34. Yayama, K., Nagaoka, M., Takano, M., and Okamoto, H. 2000. Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes. Biochim. Biophys. Acta, 1495: 69-77.